Understanding how REST affects treatment response in small cell lung cancer
Interrogating roles for REST in small cell lung cancer therapy response and resistance
['FUNDING_R01'] · FRED HUTCHINSON CANCER CENTER · NIH-11003759
This study is looking at a protein called REST in small cell lung cancer to understand how it affects treatment success, especially in less common types, so that we can find better ways to help patients like you respond to therapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11003759 on ClinicalTrials.gov |
What this research studies
This research investigates the role of a protein called REST in small cell lung cancer (SCLC) and how it influences the effectiveness of cancer therapies. The study aims to explore different subtypes of SCLC, particularly focusing on those that are less understood, to determine how REST contributes to treatment resistance. By using advanced techniques like RNA sequencing and genetically engineered mouse models, researchers will analyze how REST affects the immune response and cancer cell behavior. Patients may benefit from insights that could lead to more effective treatment strategies tailored to specific cancer subtypes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer, especially those with low-neuroendocrine subtypes.
Not a fit: Patients with non-small cell lung cancer or those who do not have the specific subtypes of SCLC being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with small cell lung cancer, particularly those who currently have limited responses to existing therapies.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune responses in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MACPHERSON, DAVID — FRED HUTCHINSON CANCER CENTER
- Study coordinator: MACPHERSON, DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy